AcelRx Pharma shares sink as FDA rejects opioid painkiller

(Reuters) – Shares of AcelRx Pharmaceuticals Inc plunged more than 60 percent on Thursday after the U.S. Food and Drug Administration declined to approve its opioid painkiller Dsuvia.
Original Article